Themis Medicare Ltd's Q3FY25 Quarter Results
- 15 Feb 2025
Result Summary
- Themis Medicare Ltd reported a 19.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 14.1%.
- Its expenses for the quarter were down by 13.5% QoQ and up 12.9% YoY.
- The net profit decreased 96.4% QoQ and decreased 92.9% YoY.
- The earnings per share (EPS) of Themis Medicare Ltd stood at 0.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 94.83 | 118.15 | 83.08 | -19.7% | 14.1% |
Total Expenses | 90.61 | 104.77 | 80.23 | -13.5% | 12.9% |
Profit Before Tax | 4.22 | 13.37 | 2.85 | -68.4% | 48.1% |
Tax | 1.14 | 3.50 | 0.85 | -67.4% | 34.1% |
Profit After Tax | 0.52 | 14.29 | 7.37 | -96.4% | -92.9% |
Earnings Per Share | 0.10 | 1.60 | 0.80 | -93.8% | -87.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Themis Medicare Ltd operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of various therapeutic drugs. The company is known for its efforts in producing innovative healthcare solutions and has a significant presence in both domestic and international markets. Themis Medicare has been involved in producing a range of pharmaceutical products, including injectables, tablets, and capsules that cater to critical care, pain management, and other therapeutic areas. As of the latest updates, any recent major developments specific to the company, such as mergers, acquisitions, or new product launches, are not available from the provided data.
Revenue
In the third quarter of the financial year 2025 (Q3FY25), Themis Medicare Ltd reported a total income of ₹94.83 crores. This marks a quarter-over-quarter (QoQ) decrease of 19.7% from the previous quarter (Q2FY25), where the total income was ₹118.15 crores. However, compared to the same quarter in the previous year (Q3FY24), there is a year-over-year (YoY) increase of 14.1%, with the total income for Q3FY24 recorded at ₹83.08 crores. These figures indicate fluctuations in the company's revenue over recent quarters and years.
Profitability
For Q3FY25, Themis Medicare Ltd's profit before tax was ₹4.22 crores, showing a significant QoQ decline of 68.4% from ₹13.37 crores in Q2FY25. However, there was a YoY increase of 48.1% from ₹2.85 crores in Q3FY24. The tax expense for Q3FY25 amounted to ₹1.14 crores, down by 67.4% from the previous quarter's ₹3.50 crores but up by 34.1% from ₹0.85 crores in Q3FY24. The profit after tax for Q3FY25 was ₹0.52 crores, representing a drastic QoQ decrease of 96.4% from ₹14.29 crores in Q2FY25 and a YoY decrease of 92.9% from ₹7.37 crores in Q3FY24. Earnings per share for Q3FY25 also fell significantly both QoQ and YoY to ₹0.10, compared to ₹1.60 in Q2FY25 and ₹0.80 in Q3FY24.
Operating Metrics
The total expenses for Themis Medicare Ltd in Q3FY25 were ₹90.61 crores, which is a reduction of 13.5% QoQ from ₹104.77 crores in Q2FY25. On a YoY basis, total expenses increased by 12.9% from ₹80.23 crores in Q3FY24. These financial metrics indicate the company's operational cost trends over recent periods. Unfortunately, without further data on specific operating metrics such as the P/E ratio, debt-to-equity ratio, or current ratio, a detailed analysis of financial ratios is not feasible based on the provided data alone.
